These data are in accordance with the findings of Kanomata and colleagues, who reported that 90% of mesothelioma cases tested in IHC extensively immunoreacted to anti-HAS1 and HAS2 antibodies, while HAS3 overexpression was evident only in 40% of the cases [41]. The gene discussed is HAS2; the disease is mesothelioma.